Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LianBio - American Depositary Shares (NQ:LIAN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about LianBio - American Depositary Shares

< Previous 1 2 Next >
LianBio Announces Voluntarily Delisting from Nasdaq
From LianBio
Via GlobeNewswire
LianBio Announces Completion of Strategic Review
LianBio to commence the wind down of its operations, including sale of remaining assets and reduction in force, delisting from Nasdaq and issuance of special cash dividend 
From LianBio
Via GlobeNewswire
LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets
From LianBio
Via GlobeNewswire
LianBio Announces Departure of Chief Financial Officer
From LianBio
Via GlobeNewswire
LianBio Announces Departure of Chief Executive Officer
From LianBio
Via GlobeNewswire
LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences
From LianBio
Via GlobeNewswire
LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
From LianBio
Via GlobeNewswire
LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From LianBio
Via GlobeNewswire
LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
From LianBio
Via GlobeNewswire
LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023
From LianBio
Via GlobeNewswire
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
From LianBio
Via GlobeNewswire
LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology
From LianBio
Via GlobeNewswire
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From LianBio
Via GlobeNewswire
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
From LianBio
Via GlobeNewswire
LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis
From LianBio
Via GlobeNewswire
LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand
From LianBio
Via GlobeNewswire
LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023
From LianBio
Via GlobeNewswire
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
From LianBio
Via GlobeNewswire
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore
From LianBio
Via GlobeNewswire
LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
From LianBio
Via GlobeNewswire
LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China
From LianBio
Via GlobeNewswire
LianBio to Participate in Upcoming Investor Conferences
From LianBio
Via GlobeNewswire
LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update
From LianBio
Via GlobeNewswire
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China
From LianBio
Via GlobeNewswire
LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients
From LianBio
Via GlobeNewswire
LianBio Promotes Pascal Qian to Chief Commercial Officer
From LianBio
Via GlobeNewswire
LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
From LianBio
Via GlobeNewswire
LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From LianBio
Via GlobeNewswire
Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore
From LianBio; Pfizer Inc.
Via GlobeNewswire
LianBio Announces President and Chief Strategy Officer Departure
From LianBio
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.